Rhumbline Advisers bought a new position in Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 10,291 shares of the company’s stock, valued at approximately $123,000.
Separately, Bank of New York Mellon Corp purchased a new position in shares of Gyre Therapeutics in the second quarter worth about $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.
Gyre Therapeutics Trading Down 1.7 %
Shares of NASDAQ GYRE opened at $12.54 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $4.80 and a 52 week high of $30.40. The business’s 50 day moving average price is $12.75 and its 200 day moving average price is $13.59.
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
- Five stocks we like better than Gyre Therapeutics
- What is a buyback in stocks? A comprehensive guide for investors
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- 3 Healthcare Dividend Stocks to Buy
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding GYRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gyre Therapeutics, Inc. (NASDAQ:GYRE – Free Report).
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.